Scarica l'app Stockscreener
1,170.50
1.24%
13.87
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$1,156.63
Aprire:
$1162.27
Volume 24 ore:
1.23M
Relative Volume:
0.39
Capitalizzazione di mercato:
$1.04T
Reddito:
$72.25B
Utile/perdita netta:
$25.28B
Rapporto P/E:
42.13
EPS:
27.781
Flusso di cassa netto:
$10.37B
1 W Prestazione:
-3.78%
1M Prestazione:
+4.32%
6M Prestazione:
+12.77%
1 anno Prestazione:
+48.26%
Intervallo 1D:
$1,141.20
$1,189.07
Intervallo di 1 settimana:
$1,134.40
$1,212.96
Portata 52W:
$623.78
$1,249.45
Lilly Eli Co Stock (LLY) Company Profile
Nome
Lilly Eli Co
Settore
Industria
Telefono
(317) 276-2000
Indirizzo
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,170.94 | 1.03T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
247.99 | 594.63B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
251.63 | 431.29B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
128.04 | 305.29B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
152.39 | 287.74B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-17 | Downgrade | HSBC Securities | Hold → Reduce |
| 2026-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2026-02-20 | Iniziato | Barclays | Overweight |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-12-16 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | Reiterato | BofA Securities | Buy |
| 2025-12-15 | Reiterato | Goldman | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-11-10 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Reiterato | BMO Capital Markets | Outperform |
| 2025-10-14 | Aggiornamento | Erste Group | Hold → Buy |
| 2025-09-17 | Downgrade | Berenberg | Buy → Hold |
| 2025-08-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Downgrade | Erste Group | Buy → Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-09-13 | Ripresa | Citigroup | Buy |
| 2024-08-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Downgrade | DZ Bank | Buy → Hold |
| 2024-02-16 | Reiterato | Morgan Stanley | Overweight |
| 2023-12-21 | Downgrade | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-20 | Ripresa | UBS | Buy |
| 2023-08-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-26 | Reiterato | Citigroup | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-24 | Reiterato | BofA Securities | Buy |
| 2023-05-24 | Reiterato | UBS | Buy |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-15 | Downgrade | Societe Generale | Hold → Sell |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-09-22 | Aggiornamento | UBS | Neutral → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-03-10 | Iniziato | Daiwa Securities | Outperform |
| 2022-01-21 | Aggiornamento | DZ Bank | Hold → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-16 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-16 | Reiterato | BofA Securities | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-11 | Aggiornamento | Berenberg | Hold → Buy |
| 2021-09-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-05 | Aggiornamento | DZ Bank | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-06-24 | Reiterato | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-09-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-04-21 | Downgrade | UBS | Buy → Neutral |
| 2020-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-18 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-04-24 | Aggiornamento | Edward Jones | Hold → Buy |
| 2019-04-11 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-03-12 | Iniziato | JP Morgan | Overweight |
| 2019-01-23 | Iniziato | UBS | Buy |
| 2018-11-26 | Downgrade | Citigroup | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-10-01 | Reiterato | SunTrust | Buy |
| 2018-09-26 | Ripresa | JP Morgan | Overweight |
Mostra tutto
Lilly Eli Co Borsa (LLY) Ultime notizie
Eli Lilly is acquiring psychedelic drug developer AtaiBeckley for $3.8 billion - Yahoo Finance Singapore
Lilly enters psychedelic drug race with up to US$3.8 billion AtaiBeckley deal - CTV News
Lilly deal to buy AtaiBeckley boosts psychedelics (LLY:NYSE) - Seeking Alpha
World's First End-To-End AI Drug Developer To Power Into Black On Lucrative Partnerships - Benzinga
Eli Lilly (LLY) Among Top Mega-Cap Healthcare Stocks with A+ Pro - GuruFocus
Lilly confirms arrival of new psychedelic age with $3.8 billion AtaiBeckley buy - The Pharma Letter
Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal - Reuters
Lilly enters psychedelic realm through $2.8bn AtaiBeckley takeover - Pharmaceutical Technology
Eli Lilly to Acquire AtaiBeckley for $2.8 Billion - Pharmaceutical Executive
Eli Lilly and Company entered into an Agreement and Plan of Merger to acquire AtaiBeckley Inc. from Apeiron Investment Group Limited and others. - marketscreener.com
Johnson & Johnson vs. Eli Lilly and: Which Pharma Giant Stock Is a Better Buy in 2026? - The Motley Fool
Eli Lilly (NYSE:LLY) Gains Momentum After FDA Drug Approval - Kalkine Media
Eli Lilly rises after AtaiBeckley purchase deal, RBC supportive - marketscreener.com
Lilly To Acquire AtaiBeckley In $2.8 Billion Deal - Pulse 2.0
Eli Lilly to acquire AtaiBeckley in deal worth up to $3.8 billion - MLex
Healthcare Investing in 2026: iShares Global Healthcare ETF Outperforms Invesco Health Care ETF - The Motley Fool
Eli Lilly to buy AtaiBeckley in $2.8bn deal - Sharecast.com
Lilly to Acquire AtaiBeckley - Contract Pharma
AtaiBeckley to be acquired by Lilly in deal valued at up to $3.8 billion - Proactive financial news
Eli Lilly confirms rumors: Makes a bid for AtaiBeckley - medwatch.com
LLY: Eli Lilly Acquires AtaiBeckley for $2.8 Billion in Psychede - GuruFocus
Lilly to Acquire AtaiBeckley in Up to $3.8 Billion Mental Health Deal - citybiz
Lilly buys into psychedelics with $3.8bn AtaiBeckley deal - pharmaphorum
Eli Lilly to acquire psychedelic treatment firm AtaiBeckley - Business Post
Lilly to acquire psychedelics drug developer AtaiBeckley for $2.8 billion - PharmaLive
ATAI Stock Soars On Eli Lilly’s $2.8B Buyout – Why Are CMPS Shares Rising Too? - Stocktwits
Eli Lilly to Buy Psychedelic Firm AtaiBeckley for Initial $2.8 Billion - WSJ
Eli Lilly to acquire psychedelics-focused biotech AtaiBeckley - STAT
Eli Lilly to acquire psychedelic drugmaker AtaiBeckley for $2.8 billion - qz.com
Eli Lilly buys psychedelic biotech backed by Peter Thiel - Financial Times
Lilly Agrees To Acquire AtaiBeckley For Upto $3.8 Bln Cash - RTTNews
Eli Lilly to acquire AtaiBeckley for $2.8 billion - Breakingthenews.net
Lilly Strikes $3.8 Billion Deal for Psychedelic Drugmaker - Bloomberg.com
Lilly to acquire AtaiBeckley for $2.8 billion upfront - Investing.com
Lilly Enters Psychedelic Drug Race With up to $3.8 Billion AtaiBeckley DealU.S. News - U.S. News - Money
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions - PR Newswire
Eli Lilly (LLY) Stock May Be Below Fair Value After FDA Cancer Drug Approval - simplywall.st
AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer - Reuters
Eli Lilly moves closer to major acquisition of US company - medwatch.com
Eli Lilly in talks to acquire AtaiBeckley, shares jump 53% - Investing.com
Lilly Said to Near Deal for Psychedelic Drugmaker AtaiBeckley - Bloomberg.com
Psychedelic drugmaker AtaiBeckley shares soar 66% on Eli Lilly buyout talks - MSN
Psychedelic drugmaker AtaiBeckley shares soar 66% on Eli Lilly buyout talks (LLY:NYSE) - Seeking Alpha
AtaiBeckley (ATAI) Stock Skyrockets 65% After-Hours on Eli Lilly Acquisition Talks - Benzinga
ATAI Stock Eyes Rocketing Back To 4-Year Highs: VC Sees Up to 105% Takeover Premium From Eli Lilly - Stocktwits
Eli Lilly in talks to buy psychedelic drugmaker AtaiBeckleyBloomberg - Investing.com
Eli Lilly Nears Deal for AtaiBeckley - Briefs Finance
Eli Lilly (LLY) in Talks for Potential Acquisition of AtaiBeckle - GuruFocus
Sanofi, Lilly back AdvanCell's $315M radiopharmaceutical push - FirstWord PHARMA
Watch Lilly Buys Psychedelic Drugmaker AtaiBeckley for $3.8 Billion - Bloomberg.com
Eli Lilly (LLY) Nears Acquisition of AtaiBeckley - GuruFocus
Lilly Eli Co Azioni (LLY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.32%
0.20%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):